Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
By Angelica Peebles,
CNBC
| 02. 21. 2025
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday, marking the end of the Bluebird’s fall from the one of the buzziest biotech firms to one that was on the cusp of running out of money.
Bluebird’s shareholders will receive $3 per share with the possibility of getting another $6.84 a share if Bluebird’s gene therapies reach $600 million in sales in any 12-month period by the end of 2027. Bluebird shares closed at $7.04 on Thursday. They fell 40% on Friday after the company announced the sale.
For more than thirty years, Bluebird has been at the forefront of creating one-time treatments that promised to cure genetic diseases. At one point, Bluebird’s market cap hovered around $9 billion as investors bought into the idea that the company could find success with its gene therapies. It’s fallen under $41 million after the company faced several scientific setbacks, separated its cancer work into another company and fell into financial despair.
The turning point came in 2018, when Bluebird...
Related Articles
By Jared Whitlock, Endpoints News | 10.09.2025
When Nirnay Murthy learned about a treatment for his toddler son’s rare condition, relief quickly gave way to disappointment.
A one-time gene therapy called Zolgensma from the Swiss drugmaker Novartis can halt spinal muscular atrophy, a deadly condition that causes...
By Meagan Parrish, PharmaVoice | 10.10.2025
When CEO Ben Lamm steps into the spotlight, it’s usually to talk about his efforts bringing extinct animals back to life. Once a far-flung idea, Lamm and the company he heads, Colossal Biosciences, have proven they can pull it off...
By Rob Stein, NPR | 09.30.2025
Scientists have created human eggs containing genes from adult skin cells, a step that someday could help women who are infertile or gay couples have babies with their own genes but would also raise difficult ethical, social and legal issues...
By Daniel Hildebrand, The Humanist | 10.01.2025
When most people hear the word eugenics, they think of dusty history textbooks and black-and-white photographs: forced sterilizations in the early 20th century, pseudoscientific charts measuring skulls, the language of “fitness” used to justify violence and exclusion. It feels like...
